Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
DGX > SEC Filings for DGX > Form 8-K on 22-Aug-2013All Recent SEC Filings

Show all filings for QUEST DIAGNOSTICS INC



Change in Directors or Principal Officers, Regulation FD Disclosure, Other

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On August 20, 2013, Mark J. Guinan, Senior Vice President and Chief Financial Officer, became an executive officer of Quest Diagnostics Incorporated (the "Company") and became a Schedule B Participant in the Company's Executive Officer Severance Plan (the "Plan"). A copy of the Plan with updated Schedules A and B is attached as Exhibit 10.1 and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure

(a) The Company announced that it recently completed the accelerated share repurchase agreement (the "ASR Agreement") entered into on April 19, 2013. Under the ASR Agreement, the Company repurchased $450 million of the Company's common stock.

Item 8.01 Other Events

(a) Since the spin-off of Quest Diagnostics Incorporated (the "Company") from Corning Incorporated in January 1997, the Company has maintained supermajority voting requirements in its Certificate of Incorporation. At the Company's 2013 annual meeting of stockholders, the Company's stockholders had the opportunity to vote on a stockholder proposal that suggested eliminating supermajority voting requirements in the Company's Certificate of Incorporation. The Board was interested in the views of the stockholders regarding the proposal, so it recommended that stockholders vote on the proposal, but did not provide a recommendation as to whether stockholders should vote for or against the proposal. A substantial majority of the Company's stockholders voted in favor of the proposal.

The merits of supermajority voting requirements have been extensively discussed. The Board is familiar with the discussions regarding supermajority voting requirements, and understands both sides of the argument. In light of the voting results on the stockholder proposal at the Company's 2013 annual meeting of stockholders, the Board carefully reconsidered the advantages and disadvantages of maintaining supermajority voting requirements, giving due consideration to the various arguments for and against supermajority voting requirements. After this review, and after considering the recommendation of the Board's Governance Committee, on August 20, 2013, the Board determined that it is advisable to eliminate the supermajority voting requirements from the Company's Certificate of Incorporation, and to recommend to the Company's stockholders at the Company's 2014 annual meeting of stockholders to approve amendments to Paragraphs 6 and 12 of the Company's Certificate of Incorporation to eliminate supermajority voting requirements.

(b) On August 20, 2013, the Company issued a press release announcing that the Company's Board of Directors authorized the Company to repurchase $1 billion of the Company's common stock. In addition to its existing capital deployment commitments, the Company plans to use approximately $300 million in net proceeds from the recent sale of the ibrutinib royalty rights to repurchase the Company's common stock as part of the Company's common stock repurchase program. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibit Description

10.1 Amended and Restated Quest Diagnostics Incorporated Executive Officer Severance Plan
99.1 Press release of Quest Diagnostics Incorporated dated August 20, 2013, announcing that the Company's Board of Directors authorized the Company to repurchase $1 billion of the Company's common stock.

  Add DGX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for DGX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.